Results
Confo Therapeutics awarded €1M VLAIO grant
VUB spin-off Confo Therapeutics announced that it has been awarded a €1 million grant from VLAIO. The grant will support the pre-clinical development of CFTX-1554, Confo’s lead candidate for neuropathic pain, which was initially discovered under a previous VLAIO research grant.
Read more
RENAISSANCE project shows energy transition can be done locally
Researchers from the Vrije Universiteit Brussel in cooperation with research and consultancy firm Deep Blue conducted a survey on the acceptance of clean technologies and how citizens would feel being both consumer and producer (prosumer) of renewable energy in their own local community.
Read more
VUB provides breakthrough in chronic pain management
Customised medicine offers solution An international team of experts has provided a breakthrough in the study of chronic pain in rheumatoid arthritis patients. “We discovered that hypersensitivity is often the cause for all kinds of chronic pain.
Read more
Pioneering research on climate reconstruction
Geologist Niels de Winter, researcher at the VUB research group AMGC (Analytical, Environmental and Geo-Chemistry) and Utrecht University was nominated for the title New Scientist Science Talent 2021.
Read more
Launch Amai! platform for AI applications
VUB project brings citizens and experts together to develop AI solutions around climate, health, mobility and work Together with Scivil, the Flemish Knowledge Center for Citizen Science, the imec-SMIT-VUB-Knowledge Center Data & Society is launching the project "amai!".
Read more
Wastewater against drought
VUB investigates whether treated wastewater via underground infiltration can help agriculture In recent years, Flanders has been confronted with long and intense periods of drought.
Read more
PRECIRIX partners with Evergreen to develop targeted cancer therapy
VUB spin-off PRECIRIX and Evergreen Theragnostics, a radiopharmaceutical contract manufacturer, announced that they have entered into an agreement whereby Evergreen will provide US-based manufacturing for PRECIRIX’s lead product candidate, CAM-H2. CAM-H2 is being evaluated i...
Read more
PharmaFluidics launches technology for routine proteomics
VUB spin-off PharmaFluidics launches its next generation µPAC™ technology for routine proteomics. PharmaFluidics’ µPAC™ micro-fluidic chips allow to separate and analyze complex biological samples into thousands of components.
Read more
Belgian technology doubles the chance of pregnancy via IVF
Fertiga is a spin-off company from one of the global IVF leading centers; UZ Brussel.
Read more
Fungi could be building material of the future
Innovative research at VUB supports transition to circular bio-based society For decades, we have been extracting materials from natural sources such as fossil fuels without considering the environmental impact. Plastic, concrete and synthetic composites are examples of such materials.
Read more